CN1842589A - 用于从组织分离并且浓缩再生细胞的系统和方法 - Google Patents
用于从组织分离并且浓缩再生细胞的系统和方法 Download PDFInfo
- Publication number
- CN1842589A CN1842589A CNA2004800246241A CN200480024624A CN1842589A CN 1842589 A CN1842589 A CN 1842589A CN A2004800246241 A CNA2004800246241 A CN A2004800246241A CN 200480024624 A CN200480024624 A CN 200480024624A CN 1842589 A CN1842589 A CN 1842589A
- Authority
- CN
- China
- Prior art keywords
- cell
- chamber
- tissue
- regenerative cell
- regenerative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 249
- 238000000034 method Methods 0.000 title abstract description 101
- 210000004027 cell Anatomy 0.000 claims abstract description 467
- 210000001519 tissue Anatomy 0.000 claims abstract description 207
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 96
- 210000000130 stem cell Anatomy 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims description 119
- 239000000243 solution Substances 0.000 claims description 61
- 238000004140 cleaning Methods 0.000 claims description 40
- 230000000712 assembly Effects 0.000 claims description 39
- 238000000429 assembly Methods 0.000 claims description 39
- 239000012266 salt solution Substances 0.000 claims description 38
- 238000000926 separation method Methods 0.000 claims description 37
- 238000005119 centrifugation Methods 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 238000001914 filtration Methods 0.000 claims description 34
- 102000029816 Collagenase Human genes 0.000 claims description 33
- 108060005980 Collagenase Proteins 0.000 claims description 33
- 229960002424 collagenase Drugs 0.000 claims description 33
- 238000000354 decomposition reaction Methods 0.000 claims description 32
- 239000000654 additive Substances 0.000 claims description 29
- 239000002699 waste material Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 230000000996 additive effect Effects 0.000 claims description 22
- 210000001789 adipocyte Anatomy 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 21
- 229920001436 collagen Polymers 0.000 claims description 21
- 239000012510 hollow fiber Substances 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 238000007789 sealing Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 9
- 238000011026 diafiltration Methods 0.000 claims description 9
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- 102000013275 Somatomedins Human genes 0.000 claims description 8
- 230000010261 cell growth Effects 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 6
- 230000002572 peristaltic effect Effects 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- -1 Unidasa Proteins 0.000 claims description 4
- 108010052014 Liberase Proteins 0.000 claims description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 239000012578 cell culture reagent Substances 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 238000001802 infusion Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 description 53
- 239000000463 material Substances 0.000 description 51
- 230000008569 process Effects 0.000 description 30
- 239000002245 particle Substances 0.000 description 23
- 238000012545 processing Methods 0.000 description 22
- 230000006870 function Effects 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 230000029087 digestion Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000002243 precursor Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000005484 gravity Effects 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 9
- 238000007443 liposuction Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000003796 beauty Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 238000005086 pumping Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000003725 endotheliocyte Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 2
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000006909 anti-apoptosis Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000005070 ripening Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002050 silicone resin Polymers 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101150091877 Ccn2 gene Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 235000015090 marinades Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229950010664 primycin Drugs 0.000 description 1
- NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940078162 triadine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
- C12M3/08—Apparatus for tissue disaggregation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0442—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0407—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
- C12M33/14—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus with filters, sieves or membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0442—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
- B04B2005/0471—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation with additional elutriation separation of different particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
身体质量指数状态 | 获得的组织的量(克) | 总的再生细胞产量(×107) |
正常 | 641±142 | 2.1±0.4 |
肥胖 | 1225±173 | 2.4±0.5 |
P值 | 0.03 | 0.6 |
描述 | 设备供应商 | 数量 | 附注 |
10毫升注射器 | Becton-Dickinson | 根据需要 | 可选,用于吸脂 |
14GA钝顶针 | 根据需要 | 可选,用于吸脂 | |
单个血液包(600毫升) | Baxter Fenwal | 1 | 主细胞处理袋;袋具有在管线上的尖头形适配器和两个空闲的尖头形口 |
具有连接器的转移包(150毫升) | Baxter Fenwal | 1 | 四边形袋用具 |
具有连接器的转移包(1升) | Baxter Fenwal | 1 | 废物袋 |
样本位置连接器 | Baxter Fenwal | 2 | |
0.9%盐水(用于注射) | Baxter Fenwal | 1 | |
14GA尖针 | Monoject | 根据需要 | 用于向袋中添加吸脂组织 |
20GA尖针 | Monoject | 3 | 用于添加胶原酶并且移除PLA细胞 |
0.2微米Sterflip过滤器 | Millipore | 1 | 用于过滤胶原酶 |
Teruflex铝密封夹 | Terumo | 4 | ME*ACS121用于临时管道密封 |
聚乙烯吡酮碘预备衬垫 | Triadine | 根据需要 | 10-3201 |
Liberase H1胶原酶 | Roche | 参看过程批注1 | |
TSCD干胶片 | Terumo | 2 | ISC*W017与TSCD无菌管道焊接机一起使用 |
描述 | 设备供应商 | 数量 | 附注 |
Sorvall Legend TEasy Set离心机 | Fisher Scientific | 1 | 75-004-367 |
转子 | Kendro/Sorvall | 1 | TTH-750转子 |
转子叶片 | Kendro/Sorvall | 4 | 75006441圆形叶片 |
用于150毫升袋的适配器 | Kendro/Sorvall | 4 | 00511 |
等离子表现物 | Baxter Fenwal | 1 | 4R4414 |
管密封件 | Sebra | 1 | 型号1060 |
TSCD无菌管道焊接机 | Terumo | 1 | 3ME*SC201AD |
Labline热摇摆器 | Labline | 1 | 4637 |
“一次性”塑料止血钳子型夹钳 | Davron | 3 | |
平衡袋用具 | 2 | 用于平衡离心机的装满水的袋 | |
生物危害的锋利物腔室 | 1 | ||
生物危害的废物腔室 | 1 |
Claims (51)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48282003P | 2003-06-25 | 2003-06-25 | |
US60/482,820 | 2003-06-25 | ||
US49646703P | 2003-08-20 | 2003-08-20 | |
US60/496,467 | 2003-08-20 | ||
PCT/US2004/020594 WO2005012480A2 (en) | 2003-06-25 | 2004-06-25 | Systems and methods for separating and concentrating regenerative cells from tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1842589A true CN1842589A (zh) | 2006-10-04 |
CN1842589B CN1842589B (zh) | 2012-04-25 |
Family
ID=34118676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800246241A Expired - Lifetime CN1842589B (zh) | 2003-06-25 | 2004-06-25 | 用于从组织分离并且浓缩再生细胞的系统和方法 |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP2380970B1 (zh) |
JP (2) | JP2007524396A (zh) |
KR (1) | KR101127305B1 (zh) |
CN (1) | CN1842589B (zh) |
AU (1) | AU2004260937B2 (zh) |
BR (1) | BRPI0411798A (zh) |
CA (1) | CA2530630A1 (zh) |
HK (1) | HK1096424A1 (zh) |
IL (1) | IL172800A0 (zh) |
MX (1) | MXPA06000062A (zh) |
WO (1) | WO2005012480A2 (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869761A (zh) * | 2009-10-27 | 2013-01-09 | 普瑞生物技术公司 | 再生细胞提取系统 |
CN103203043A (zh) * | 2012-01-12 | 2013-07-17 | 刘云松 | 用于分离原代脂肪干细胞的储脂桶及其使用方法 |
CN103476920A (zh) * | 2011-03-08 | 2013-12-25 | 莱顿大学 | 处理细胞和相关结构的设备及方法 |
CN104302301A (zh) * | 2011-12-07 | 2015-01-21 | 西托维拉公司 | 用于样品处理的方法和装置 |
CN104758979A (zh) * | 2014-01-02 | 2015-07-08 | Psc化妆品有限公司 | 获得、产生和植入血纤蛋白凝块生物材料的方法和设备 |
CN105026545A (zh) * | 2013-03-04 | 2015-11-04 | 瑞士干细胞基金会 | 用于从组织样本提取细胞的系统 |
CN105934155A (zh) * | 2013-09-19 | 2016-09-07 | 再生医疗技术公司 | 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法 |
CN107249655A (zh) * | 2015-02-02 | 2017-10-13 | 凯拉斯丹姆技术有限公司 | 使用脂肪源再生细胞和脂肪组织以刺激毛囊龛的新方法和装置 |
CN107735120A (zh) * | 2015-07-13 | 2018-02-23 | 美国血液技术公司 | 用于从回收的血液中清除脂肪的系统和方法 |
CN109415675A (zh) * | 2016-03-17 | 2019-03-01 | 辛诺瓦生命科学股份有限公司 | 使用冲击波或机械冲击分离、解离和/或裂解细胞的方法 |
CN111678750A (zh) * | 2020-04-24 | 2020-09-18 | 苏州格目软件技术有限公司 | 一种基于离心分离的生物检测平台 |
CN112912482A (zh) * | 2018-07-27 | 2021-06-04 | 尤尼沃尔塞尔斯技术股份公司 | 制备生物分子的系统和方法 |
CN113660961A (zh) * | 2018-12-13 | 2021-11-16 | 科力果疗法公司 | 细胞分离装置及使用方法 |
CN113748199A (zh) * | 2019-03-26 | 2021-12-03 | 株式会社美加细胞 | 细胞悬浮液处理装置 |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8105580B2 (en) | 2001-12-07 | 2012-01-31 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to promote wound healing |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
JP4653952B2 (ja) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法 |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
EP1743021B1 (en) * | 2004-03-19 | 2014-03-26 | Cytori Therapeutics, Inc. | Method of preparing regenerative cells on a cell carrier and cell carrier containment device |
ATE478942T1 (de) * | 2004-07-01 | 2010-09-15 | Cytori Therapeutics Inc | Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen |
CN101031639A (zh) * | 2004-07-01 | 2007-09-05 | 马克罗珀尔生物外科公司 | 使用再生细胞促进伤口愈合的方法 |
JP4731556B2 (ja) * | 2004-07-02 | 2011-07-27 | サイトリ セラピューティクス インコーポレイテッド | 臨床的に安全な脂肪組織由来再生細胞を単離し、使用するためのシステムおよび方法 |
US8062286B2 (en) | 2005-03-23 | 2011-11-22 | Shippert Ronald D | Tissue transplantation method and apparatus |
US8622997B2 (en) | 2005-03-23 | 2014-01-07 | Ronald D. Shippert | Tissue transfer method and apparatus |
US9581942B1 (en) | 2005-03-23 | 2017-02-28 | Shippert Enterprises, Llc | Tissue transfer method and apparatus |
US7794449B2 (en) | 2005-03-23 | 2010-09-14 | Shippert Ronald D | Tissue transplantation method and apparatus |
US7789872B2 (en) | 2005-03-23 | 2010-09-07 | Shippert Ronald D | Tissue transplantation method and apparatus |
US7780649B2 (en) | 2005-03-23 | 2010-08-24 | Shippert Ronald D | Tissue transplantation method and apparatus |
EP1885382B1 (en) * | 2005-05-25 | 2011-03-02 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
WO2007046501A1 (ja) | 2005-10-21 | 2007-04-26 | Kaneka Corporation | 幹細胞の分離材および分離方法 |
JP4928831B2 (ja) * | 2006-05-25 | 2012-05-09 | 株式会社カネカ | 自動培養装置 |
JP5038336B2 (ja) * | 2007-02-16 | 2012-10-03 | オリンパス株式会社 | 脂肪消化終了判定装置および脂肪組織消化装置 |
JP2008212021A (ja) * | 2007-03-01 | 2008-09-18 | Olympus Corp | 生体組織の分解状況判定方法および生体組織分解装置 |
CN101668843A (zh) * | 2007-04-27 | 2010-03-10 | 东洋制罐株式会社 | 细胞培养装置、细胞培养体系及细胞培养方法 |
JP2008278822A (ja) | 2007-05-11 | 2008-11-20 | Olympus Corp | 生体組織分解方法 |
JP5190861B2 (ja) | 2007-05-11 | 2013-04-24 | オリンパス株式会社 | 生体組織分解方法 |
JP2009095309A (ja) * | 2007-10-18 | 2009-05-07 | Olympus Corp | 生体組織分解装置および生体組織分解方法 |
JP2009136172A (ja) | 2007-12-04 | 2009-06-25 | Olympus Corp | 細胞処理装置 |
JP2009136168A (ja) * | 2007-12-04 | 2009-06-25 | Olympus Corp | 細胞分離装置 |
ATE528077T1 (de) * | 2007-12-07 | 2011-10-15 | Miltenyi Biotec Gmbh | Zentrifuge zur trennung einer probe in mindestens zwei komponenten |
GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
JP2009189281A (ja) * | 2008-02-13 | 2009-08-27 | Olympus Corp | 細胞処理装置 |
KR101005938B1 (ko) * | 2008-03-28 | 2011-01-06 | 이희영 | 지지체의 제조방법 및 장치 |
FR2931838B1 (fr) * | 2008-06-02 | 2010-06-11 | Millipore Corp | Installation pour traiter un liquide biologique. |
KR101044371B1 (ko) * | 2008-06-05 | 2011-06-29 | 이희영 | 줄기세포 분리를 위한 혼합장치 |
BRPI0917993B8 (pt) | 2008-08-14 | 2021-05-25 | Mesoblast Int Sarl | composições de célula-tronco mesenquimal purificada |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
JP2010075066A (ja) | 2008-09-24 | 2010-04-08 | Olympus Corp | 遠心分離容器 |
EP2350274B1 (en) | 2008-10-21 | 2019-01-23 | The General Hospital Corporation | Cell transplantation |
JP2010127620A (ja) * | 2008-11-25 | 2010-06-10 | Olympus Corp | 生体組織処理装置 |
JP2010148450A (ja) | 2008-12-25 | 2010-07-08 | Olympus Corp | 細胞洗浄方法 |
JP2010207318A (ja) * | 2009-03-09 | 2010-09-24 | Olympus Corp | 生体組織採取装置 |
KR101644534B1 (ko) | 2009-05-01 | 2016-08-01 | 비미니 테크놀로지스 엘엘씨 | 조직 및 세포 부유화 이식편의 최적화 시스템, 방법 및 조성물 |
KR101316573B1 (ko) * | 2009-10-27 | 2013-10-15 | 도병록 | 재생성 세포 추출유닛 및 재생성 세포 추출시스템 |
JP5710885B2 (ja) * | 2010-02-25 | 2015-04-30 | オリンパス株式会社 | 脂肪由来細胞の賦活化方法および移植材の製造方法 |
JP5821847B2 (ja) * | 2010-07-01 | 2015-11-24 | 株式会社カネカ | 細胞培養用ディスポセット、細胞培養装置及び細胞調製方法 |
WO2012019103A2 (en) * | 2010-08-06 | 2012-02-09 | The General Hospital Corporation D/B/A | System and apparatus for cell treatment |
JP5837742B2 (ja) | 2010-08-27 | 2015-12-24 | 学校法人東京女子医科大学 | 細胞単離装置 |
WO2012048275A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US8887770B1 (en) | 2011-03-17 | 2014-11-18 | Ronald D. Shippert | Vessel fill control method and apparatus |
US10934519B2 (en) | 2011-07-29 | 2021-03-02 | Global Life Sciences Solutions Usa Llc | Systems, methods and control laws for cell harvesting |
US20150004702A1 (en) * | 2011-08-29 | 2015-01-01 | Stempeutics Research Private Limited | System for isolating stromal vascular fraction (svf) cells from the adipose tissue and a method thereof |
US9603356B2 (en) | 2011-10-24 | 2017-03-28 | Kaneka Corporation | Method for producing cell concentrate |
DE102013209718B4 (de) * | 2012-06-22 | 2015-09-10 | Human Med Ag | Vorrichtung zum Separieren von adulten Stammzellen |
BR112015001905A2 (pt) * | 2012-08-27 | 2017-07-04 | Stempeutics Res Private Limited | sistema de misturador e separador de múltiplos planos (mpms) |
US9624207B2 (en) | 2012-08-27 | 2017-04-18 | Hetero Research Foundation | Polymorphs of azilsartan medoxomil |
EP2891710B1 (en) | 2012-08-30 | 2018-10-17 | Kaneka Corporation | Method for producing cell concentrate |
US9468709B2 (en) | 2012-11-12 | 2016-10-18 | Shippert Enterprises, Llc | Syringe fill method and apparatus |
US20140162355A1 (en) * | 2012-12-07 | 2014-06-12 | Antria, Inc. | Formulations Containing and Kit for Using Adipose-Derived Stem Cells and Use Thereof |
US9580678B2 (en) | 2013-06-21 | 2017-02-28 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device |
KR101354959B1 (ko) * | 2013-07-09 | 2014-01-22 | 김태영 | 줄기세포 분리기 |
CN105408467A (zh) | 2013-07-23 | 2016-03-16 | 株式会社钟化 | 细胞浓缩液的制造方法以及细胞悬浊液处理系统 |
KR101709770B1 (ko) * | 2013-10-18 | 2017-02-24 | 메디칸(주) | 소립자 물질 정제장치 및 정제방법 |
WO2015071829A1 (en) | 2013-11-13 | 2015-05-21 | Stempeutics Research Private Limited | A system and method for processing of biological tissue samples |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
KR101594539B1 (ko) * | 2014-02-17 | 2016-02-16 | 한국기초과학지원연구원 | 세포 응집용 농축 시험관 |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
WO2015149098A1 (de) | 2014-03-31 | 2015-10-08 | Liporegena Gmbh | Vorrichtung zur entnahme und portionierung von fettgewebe |
US10772997B2 (en) | 2014-05-15 | 2020-09-15 | Ronald D. Shippert | Tissue parcelization method and apparatus |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
KR101698018B1 (ko) * | 2015-09-02 | 2017-01-19 | 주식회사 베스테크 | 의료용 재생성세포 추출장치 |
US10722540B1 (en) | 2016-02-01 | 2020-07-28 | The Regents Of The University Of California | Microfluidic device and method for shear stress-induced transformation of cells |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | CELL EXPANSION |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
JP7072228B2 (ja) | 2016-06-08 | 2022-05-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 組織および細胞を処理するための方法および装置 |
WO2018031654A1 (en) * | 2016-08-09 | 2018-02-15 | Arteriocyte, Inc. | Device and methods for harvesting fat derived microvessel segments |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
JP6256786B1 (ja) * | 2017-04-12 | 2018-01-10 | 学校法人福岡大学 | 不妊症の処置に用いられる医薬組成物およびその製造方法 |
JP7282679B2 (ja) | 2017-09-15 | 2023-05-29 | 株式会社カネカ | 細胞含有試料からの細胞の遊離方法 |
WO2019059279A1 (ja) * | 2017-09-20 | 2019-03-28 | 株式会社カネカ | 細胞懸濁液を調製するためのデバイス、システム及び方法 |
EP3461511B1 (en) * | 2017-09-29 | 2022-04-20 | Fenwal, Inc. | Systems and methods for processing large volumes of biological fluid |
GB201720405D0 (en) | 2017-12-07 | 2018-01-24 | Biosafe Sa | A bioprocessing system |
KR102196527B1 (ko) | 2017-12-21 | 2020-12-31 | 한양대학교 산학협력단 | 적혈구계 세포 배양 중 적혈구를 수거하기 위한 시스템 및 방법 |
CN108106922A (zh) * | 2018-01-31 | 2018-06-01 | 迈克医疗电子有限公司 | 一种浓缩混匀机构 |
WO2022094613A1 (en) * | 2020-10-29 | 2022-05-05 | Renovacare Sciences Corp. | Cell isolation device and methods of use |
JP2024511064A (ja) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | 細胞捕獲及び増殖 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146172A (en) * | 1977-10-18 | 1979-03-27 | Baxter Travenol Laboratories, Inc. | Centrifugal liquid processing system |
US4526515A (en) * | 1979-12-06 | 1985-07-02 | Baxter Travenol Laboratories, Inc. | Fluid pumping assembly including a prepackaged fluid circuit module |
JPS5990649A (ja) * | 1982-11-12 | 1984-05-25 | Hitachi Koki Co Ltd | 無菌式連続遠心分離システム |
JPH01141583A (ja) * | 1987-11-27 | 1989-06-02 | Shimadzu Corp | 細胞処理チャンバ |
JP2564611B2 (ja) * | 1988-06-13 | 1996-12-18 | 株式会社日立製作所 | 生物細胞用遠心分離装置及び細胞の分離方法 |
JPH0666B2 (ja) * | 1989-05-02 | 1994-01-05 | 倉敷紡績株式会社 | Dnaの単離精製法 |
US5641622A (en) * | 1990-09-13 | 1997-06-24 | Baxter International Inc. | Continuous centrifugation process for the separation of biological components from heterogeneous cell populations |
JPH0675497B2 (ja) * | 1990-11-15 | 1994-09-28 | 倉敷紡績株式会社 | プラスミド分離装置 |
JP2637297B2 (ja) * | 1991-02-22 | 1997-08-06 | 帝人株式会社 | 遠心分離装置 |
NZ242533A (en) * | 1991-05-03 | 1995-05-26 | Becton Dickinson Co | Device for collecting and processing fat tissue; vessel with rinsing and digesting chamber, drain chamber and isolation chamber |
JP3331398B2 (ja) * | 1993-05-28 | 2002-10-07 | バクスター、インターナショナル、インコーポレイテッド | 不均質な細胞混合物から特定の細胞集団を分離するための方法、装置およびシステム |
US6238908B1 (en) | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
US6280473B1 (en) | 1996-08-19 | 2001-08-28 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US5919234A (en) | 1996-08-19 | 1999-07-06 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
US6269716B1 (en) | 1998-11-18 | 2001-08-07 | Macropore, Inc. | High-torque resorbable screws |
CA2327789C (en) | 1998-04-07 | 2007-09-04 | Macropore, Inc. | Membrane with tissue-guiding surface corrugations |
US6001642A (en) | 1998-06-29 | 1999-12-14 | Wyle Laboratories, Inc. Life Sciences | Bioreactor and cell culturing processes using the bioreactor |
JP4195250B2 (ja) * | 1999-03-12 | 2008-12-10 | 株式会社神鋼環境ソリューション | ビール等の発酵食品類の製造方法 |
JP4014350B2 (ja) * | 1999-03-12 | 2007-11-28 | 株式会社神鋼環境ソリューション | 酵母液貯留用攪拌槽と、その攪拌槽を用いたビール等の発酵食品類の製造方法、並びにその攪拌槽に具備された攪拌翼 |
AU3081801A (en) | 1999-11-15 | 2001-05-30 | Chemclean Corporation | Bio-burden visualization system |
JP3524835B2 (ja) * | 2000-02-25 | 2004-05-10 | 財団法人地球環境産業技術研究機構 | 光合成培養装置及び培養方法 |
PT1265550E (pt) | 2000-03-10 | 2005-10-31 | Mast Biosurgery Ag | Micro reabsorvivel para atenuacao de tecido cicatricial |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
AU2002211449A1 (en) | 2000-10-04 | 2002-04-15 | James Peter Amis | Non-scatterable, radio-opaque marker for medical imaging applications |
US20030054331A1 (en) * | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
JP4653952B2 (ja) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法 |
-
2004
- 2004-06-25 WO PCT/US2004/020594 patent/WO2005012480A2/en active Application Filing
- 2004-06-25 EP EP11156001.7A patent/EP2380970B1/en not_active Expired - Lifetime
- 2004-06-25 CN CN2004800246241A patent/CN1842589B/zh not_active Expired - Lifetime
- 2004-06-25 CA CA002530630A patent/CA2530630A1/en not_active Abandoned
- 2004-06-25 JP JP2006517708A patent/JP2007524396A/ja active Pending
- 2004-06-25 MX MXPA06000062A patent/MXPA06000062A/es active IP Right Grant
- 2004-06-25 KR KR1020057024986A patent/KR101127305B1/ko active IP Right Grant
- 2004-06-25 EP EP04777155A patent/EP1648999A4/en not_active Withdrawn
- 2004-06-25 AU AU2004260937A patent/AU2004260937B2/en not_active Ceased
- 2004-06-25 BR BRPI0411798-0A patent/BRPI0411798A/pt not_active Application Discontinuation
-
2005
- 2005-12-25 IL IL172800A patent/IL172800A0/en unknown
-
2007
- 2007-04-02 HK HK07103532.2A patent/HK1096424A1/xx not_active IP Right Cessation
-
2011
- 2011-09-30 JP JP2011217918A patent/JP5604397B2/ja not_active Expired - Lifetime
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869761A (zh) * | 2009-10-27 | 2013-01-09 | 普瑞生物技术公司 | 再生细胞提取系统 |
CN103476920A (zh) * | 2011-03-08 | 2013-12-25 | 莱顿大学 | 处理细胞和相关结构的设备及方法 |
CN103476920B (zh) * | 2011-03-08 | 2017-05-17 | 莱顿大学 | 处理细胞和相关结构的设备及方法 |
CN104302301A (zh) * | 2011-12-07 | 2015-01-21 | 西托维拉公司 | 用于样品处理的方法和装置 |
CN103203043A (zh) * | 2012-01-12 | 2013-07-17 | 刘云松 | 用于分离原代脂肪干细胞的储脂桶及其使用方法 |
CN105026545B (zh) * | 2013-03-04 | 2017-11-24 | 瑞士干细胞基金会 | 用于从组织样本提取细胞的系统 |
CN105026545A (zh) * | 2013-03-04 | 2015-11-04 | 瑞士干细胞基金会 | 用于从组织样本提取细胞的系统 |
CN105934155A (zh) * | 2013-09-19 | 2016-09-07 | 再生医疗技术公司 | 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法 |
CN104758979A (zh) * | 2014-01-02 | 2015-07-08 | Psc化妆品有限公司 | 获得、产生和植入血纤蛋白凝块生物材料的方法和设备 |
CN107249655A (zh) * | 2015-02-02 | 2017-10-13 | 凯拉斯丹姆技术有限公司 | 使用脂肪源再生细胞和脂肪组织以刺激毛囊龛的新方法和装置 |
CN107735120A (zh) * | 2015-07-13 | 2018-02-23 | 美国血液技术公司 | 用于从回收的血液中清除脂肪的系统和方法 |
CN109415675A (zh) * | 2016-03-17 | 2019-03-01 | 辛诺瓦生命科学股份有限公司 | 使用冲击波或机械冲击分离、解离和/或裂解细胞的方法 |
US11866732B2 (en) | 2016-03-17 | 2024-01-09 | Synova Life Sciences, Inc. | Separation, dissociation and/or disaggregation of cells using shockwaves or mechanical impacts |
CN112912482A (zh) * | 2018-07-27 | 2021-06-04 | 尤尼沃尔塞尔斯技术股份公司 | 制备生物分子的系统和方法 |
CN113660961A (zh) * | 2018-12-13 | 2021-11-16 | 科力果疗法公司 | 细胞分离装置及使用方法 |
CN113748199A (zh) * | 2019-03-26 | 2021-12-03 | 株式会社美加细胞 | 细胞悬浮液处理装置 |
CN111678750A (zh) * | 2020-04-24 | 2020-09-18 | 苏州格目软件技术有限公司 | 一种基于离心分离的生物检测平台 |
Also Published As
Publication number | Publication date |
---|---|
HK1096424A1 (en) | 2007-06-01 |
CA2530630A1 (en) | 2005-02-10 |
EP1648999A4 (en) | 2006-09-06 |
MXPA06000062A (es) | 2006-04-07 |
JP5604397B2 (ja) | 2014-10-08 |
WO2005012480A2 (en) | 2005-02-10 |
BRPI0411798A (pt) | 2006-08-08 |
EP2380970B1 (en) | 2017-12-20 |
CN1842589B (zh) | 2012-04-25 |
EP1648999A2 (en) | 2006-04-26 |
AU2004260937A1 (en) | 2005-02-10 |
JP2012075439A (ja) | 2012-04-19 |
AU2004260937B2 (en) | 2010-05-13 |
EP2380970A1 (en) | 2011-10-26 |
JP2007524396A (ja) | 2007-08-30 |
IL172800A0 (en) | 2006-06-11 |
WO2005012480A3 (en) | 2005-06-02 |
KR20060030861A (ko) | 2006-04-11 |
KR101127305B1 (ko) | 2012-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1842589A (zh) | 用于从组织分离并且浓缩再生细胞的系统和方法 | |
US7514075B2 (en) | Systems and methods for separating and concentrating adipose derived stem cells from tissue | |
CN1878470A (zh) | 在周围血管疾病和相关病症的治疗中使用再生细胞的方法 | |
US10119113B2 (en) | Systems for isolating and using clinically safe adipose derived regenerative cells | |
JP4731556B2 (ja) | 臨床的に安全な脂肪組織由来再生細胞を単離し、使用するためのシステムおよび方法 | |
US20050048036A1 (en) | Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues | |
CN101443023A (zh) | 使用脂肪组织来源的细胞治疗心血管病症的方法 | |
CN101031639A (zh) | 使用再生细胞促进伤口愈合的方法 | |
KR20040063167A (ko) | 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법 | |
US20220267712A1 (en) | Cell isolation for use in automated bioreactors | |
WO2012122603A1 (en) | Cell processing method and device | |
CN102204928B (zh) | 再生细胞用于促进伤口愈合的应用 | |
CN102861105A (zh) | 使用脂肪组织来源的细胞治疗心血管病症的方法 | |
WO2006014158A1 (en) | Treating disorders by administering regenerative cells. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1096424 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1096424 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210420 Address after: J, 1st floor, building 1, No. 1185, Huyi Road, Jiading District, Shanghai Patentee after: Shanghai taorui Biotechnology Co.,Ltd. Address before: California, USA Patentee before: MACROPORE BIOSURGERY, Inc. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20120425 |